AstraZeneca’s Phase III SERENA‑6 trial shows camizestrant plus CDK4/6 inhibition significantly extends progression‑free survival, validates ctDNA‑guided treatment switching, and delays chemotherapy in HR‑positive, HER2‑negative advanced breast cancer with ESR1 mutations.
Written By: Farha Farheen, PharmD
Reviewed By: Pharmacally Editorial Team
AstraZeneca has reported updated Phase III SERENA-6 results showing that switching patients with HR-positive, HER2-negative advanced breast cancer to camizestrant plus a CDK4/6 inhibitor after detection of an emerging ESR1 mutation significantly extended disease control compared with continued aromatase inhibitor (AI) therapy.
Presented at the 2026 ASCO Annual Meeting, the findings support a ctDNA-guided treatment strategy that intervenes before clinical disease progression.
Camizestrant reduced the risk of disease progression or death by 55% versus continued AI therapy (HR 0.45; 95% CI: 0.34–0.59; p<0.00001). Median progression-free survival (PFS) reached 16.8 months compared with 9.2 months, representing a 7.6-month improvement.
Trial Design and Clinical Context
SERENA-6 (NCT04964934) is a global Phase III trial that enrolled 315 patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer receiving first-line treatment with an AI and a CDK4/6 inhibitor. Patients with newly emerging ESR1 mutations detected through routine circulating tumor DNA (ctDNA) monitoring before disease progression were randomized to switch to camizestrant or continue standard endocrine therapy.
Camizestrant is an investigational oral selective estrogen receptor degrader (SERD) developed to overcome endocrine resistance driven by ESR1 mutations, a common mechanism of treatment failure in HR-positive breast cancer.
Extended Benefit Beyond Initial Progression
The benefit extended beyond first progression. Final analysis of the key secondary endpoint, second progression-free survival (PFS2), showed a 37% reduction in the risk of second progression or death with camizestrant (HR 0.63; 95% CI: 0.46–0.86; p=0.00373). Median PFS2 reached 25.7 months versus 19.1 months with standard therapy.
Camizestrant also delayed the need for more intensive treatments. Chemotherapy or antibody-drug conjugate (ADC)-free survival improved to 22.6 months compared with 18.7 months in the comparator arm (HR 0.64; p=0.00375).
ctDNA-Guided Intervention Validated
Patients who switched to camizestrant achieved a median 99% reduction in total ctDNA by week eight, with 51% achieving complete ctDNA clearance. In contrast, patients who remained on AI therapy experienced a median 64% increase in ctDNA, while only 1.9% achieved ctDNA clearance.
Exploratory analyses linked ctDNA clearance with improved survival outcomes, providing prospective evidence that molecular monitoring can identify endocrine resistance early and support treatment changes before clinical progression occurs.
Safety and Regulatory Outlook
The safety profile of camizestrant combined with palbociclib, ribociclib, or abemaciclib remained consistent with previous reports. No new safety concerns emerged, and discontinuation rates were low and similar between treatment arms.
Camizestrant is approved in the United Arab Emirates and Saudi Arabia, while the European Medicines Agency’s CHMP has issued a positive opinion supporting approval in the European Union. Regulatory reviews remain ongoing in the United States, Japan, and other markets, with the FDA recently extending its review timeline to evaluate the updated SERENA-6 dataset. Overall survival data remain immature at 30% maturity, although current analyses show a numerical trend favoring camizestrant.
Clinical Paradigm Shift
SERENA-6 is the first registrational Phase III trial to use ctDNA monitoring to guide a treatment switch before disease progression. The findings suggest that earlier intervention against molecular resistance can prolong endocrine therapy benefit and delay the need for chemotherapy or ADCs in HR-positive, HER2-negative advanced breast cancer.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.